Icthiovac VR/PD is an injectable vaccine containing four different antigens (P. damselae subs. piscicida, L. anguillarum serotype O1, L. anguillarum serotype O2a, L. anguillarum serotype O2b) and Aquamun, Hipra’s adjuvant for aquaculture. According to Hipra, it confers strong protection against Vibriosis and Pasteurellosis, it offers long-lasting immunisation, combined with a reduced inflammatory reaction and less internal damage.
The negative impact of these two classic pathologies is becoming an increasing concern amongst Mediterranean producers, mainly due to the high prevalence resulting from the intensification of farming and the existence of natural reservoirs in the wild.
Participants at the launch, which took place on 6 March, were welcomed by Marta Perelló (Aqua Business Unit Coordinator at Hipra), who highlighted the companiy’s distinctive values: quality, innovation and commitment, with animal health prevention as its main focus.
Continuing with the talks, Agnès Callol (Researcher and Project Manager at Hipra’s Biological R&D Department) briefly presented all the different trials which were carried out during development of the vaccine, mainly focusing on the safety and efficacy aspects.
To conclude the technical sessions, Erik Díaz (Product Manager at Hipra) spoke about the current situation of Mediterranean aquaculture in terms of vaccination; from a practical point of view as well as the different important aspects which need to be taken into account when planning a vaccination. Fish and vaccine performance, together with vaccination monitoring, were also topics discussed.
